Belfast, UK. 26th October, 2023.
CV6 Therapeutics Inc., today announced that its CEO and Founder, Dr Robert Ladner will be attending Bio-Europe, to be held on the 6th-8th November in Munich, Germany. CV6 Therapeutics is a drug development company focussed on developing value-based, first-in-class medications that are scalable to address global unmet medical needs
BIO-Europe convenes over 5,500 attendees, representing 60 countries and 2,220+ companies, making the event the industry’s largest gathering of biopharma professionals in Europe and is widely considered to be the ‘must attend’ B2B partnering conference in Europe.
Dr Ladner, who will be in attendance for the duration of the event said, “Bio-Europe represents a unique opportunity to meet and build relationships with the foremost leaders in biotech, pharma and financing. These partnerships are critical in advancing CV6 Therapeutics to the next level in our strategic vision.”
CV6 Therapeutics’ first oncology clinical candidate, CV6-168, is set to enter a first-in-human phase 1a trial in early 2024. CV6-168 is a first-in-class DNA uracilation agent that specifically targets the enzyme dUTPase. Inhibition of dUTPase in combination with thymidylate synthase (TS) inhibitors (e.g., 5-FU and pemetrexed) causes the misincorporation of uracil into DNA during cancer cell replication inducing DNA damage, potent activation of the innate immune system, and cancer cell death.
Dr Ladner will be available to discuss the clinical strategy for CV6-168 and upcoming financing requirements for the Phase 1b clinical trial. Meetings can be arranged via the Bio-Europe ‘PartneringONE’ hub or by email to firstname.lastname@example.org
CV6 Therapeutics is developing value-based, first-in-class medications that are scalable to address global unmet medical needs in the oncology and inflammatory disease markets. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, or to contact us, click here: http://www.cv6t.com